The main mechanism of action of the COVID-19 neutralizing antibody drugs is to neutralize the new coronavirus and prevent the virus from being adsorbed on susceptible cells, thereby blocking the virus or its genetic material from entering the intracellular proliferation.

The global COVID-19 Neutralizing Antibody Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for COVID-19 Neutralizing Antibody Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Neutralizing Antibody Drugs.

Report Scope

The COVID-19 Neutralizing Antibody Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global COVID-19 Neutralizing Antibody Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the COVID-19 Neutralizing Antibody Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of COVID-19 Neutralizing Antibody Drugs Market Report

Report Metric	Details
Report Name	COVID-19 Neutralizing Antibody Drugs Market
CAGR	5%
Segment by Type	ACE2 Fusion Protein Neutralizing Antibody
Segment by Application	Hospital Clinic
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Tychan, AstraZeneca, Molecular Partners AG/诺华, Eli Lilly, Regeneron Pharmaceuticals, Abpro, Shanghai Junshi Biosciences, Brii Biosciences, Mabwell Bioscience, Sinocelltech, BeiGene
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of COVID-19 Neutralizing Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of COVID-19 Neutralizing Antibody Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the COVID-19 Neutralizing Antibody Drugs Market report?

Ans: The main players in the COVID-19 Neutralizing Antibody Drugs Market are Tychan, AstraZeneca, Molecular Partners AG/诺华, Eli Lilly, Regeneron Pharmaceuticals, Abpro, Shanghai Junshi Biosciences, Brii Biosciences, Mabwell Bioscience, Sinocelltech, BeiGene

What are the Application segmentation covered in the COVID-19 Neutralizing Antibody Drugs Market report?

Ans: The Applications covered in the COVID-19 Neutralizing Antibody Drugs Market report are Hospital, Clinic

What are the Type segmentation covered in the COVID-19 Neutralizing Antibody Drugs Market report?

Ans: The Types covered in the COVID-19 Neutralizing Antibody Drugs Market report are ACE2 Fusion Protein, Neutralizing Antibody

1 COVID-19 Neutralizing Antibody Drugs Market Overview

1.1 Product Overview and Scope of COVID-19 Neutralizing Antibody Drugs

1.2 COVID-19 Neutralizing Antibody Drugs Segment by Type

1.2.1 Global COVID-19 Neutralizing Antibody Drugs Market Value Comparison by Type (2024-2030)

1.2.2 ACE2 Fusion Protein

1.2.3 Neutralizing Antibody

1.3 COVID-19 Neutralizing Antibody Drugs Segment by Application

1.3.1 Global COVID-19 Neutralizing Antibody Drugs Market Value by Application: (2024-2030)

1.3.2 Hospital

1.3.3 Clinic

1.4 Global COVID-19 Neutralizing Antibody Drugs Market Size Estimates and Forecasts

1.4.1 Global COVID-19 Neutralizing Antibody Drugs Revenue 2019-2030

1.4.2 Global COVID-19 Neutralizing Antibody Drugs Sales 2019-2030

1.4.3 Global COVID-19 Neutralizing Antibody Drugs Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 COVID-19 Neutralizing Antibody Drugs Market Competition by Manufacturers

2.1 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Manufacturers (2019-2024)

2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Manufacturers (2019-2024)

2.3 Global COVID-19 Neutralizing Antibody Drugs Average Price by Manufacturers (2019-2024)

2.4 Global COVID-19 Neutralizing Antibody Drugs Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Product Type & Application

2.7 COVID-19 Neutralizing Antibody Drugs Market Competitive Situation and Trends

2.7.1 COVID-19 Neutralizing Antibody Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest COVID-19 Neutralizing Antibody Drugs Players Market Share by Revenue

2.7.3 Global COVID-19 Neutralizing Antibody Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 COVID-19 Neutralizing Antibody Drugs Retrospective Market Scenario by Region

3.1 Global COVID-19 Neutralizing Antibody Drugs Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global COVID-19 Neutralizing Antibody Drugs Global COVID-19 Neutralizing Antibody Drugs Sales by Region: 2019-2030

3.2.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Region: 2019-2024

3.2.2 Global COVID-19 Neutralizing Antibody Drugs Sales by Region: 2025-2030

3.3 Global COVID-19 Neutralizing Antibody Drugs Global COVID-19 Neutralizing Antibody Drugs Revenue by Region: 2019-2030

3.3.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Region: 2019-2024

3.3.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Region: 2025-2030

3.4 North America COVID-19 Neutralizing Antibody Drugs Market Facts & Figures by Country

3.4.1 North America COVID-19 Neutralizing Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2030)

3.4.3 North America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe COVID-19 Neutralizing Antibody Drugs Market Facts & Figures by Country

3.5.1 Europe COVID-19 Neutralizing Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2030)

3.5.3 Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific COVID-19 Neutralizing Antibody Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific COVID-19 Neutralizing Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2030)

3.6.3 Asia Pacific COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America COVID-19 Neutralizing Antibody Drugs Market Facts & Figures by Country

3.7.1 Latin America COVID-19 Neutralizing Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2030)

3.7.3 Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa COVID-19 Neutralizing Antibody Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa COVID-19 Neutralizing Antibody Drugs Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2030)

3.8.3 Middle East and Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2019-2030)

4.1.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2019-2024)

4.1.2 Global COVID-19 Neutralizing Antibody Drugs Sales by Type (2025-2030)

4.1.3 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2019-2030)

4.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2019-2030)

4.2.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2019-2024)

4.2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Type (2025-2030)

4.2.3 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2019-2030)

4.3 Global COVID-19 Neutralizing Antibody Drugs Price by Type (2019-2030)

5 Segment by Application

5.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2019-2030)

5.1.1 Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2019-2024)

5.1.2 Global COVID-19 Neutralizing Antibody Drugs Sales by Application (2025-2030)

5.1.3 Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2019-2030)

5.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2019-2030)

5.2.1 Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2019-2024)

5.2.2 Global COVID-19 Neutralizing Antibody Drugs Revenue by Application (2025-2030)

5.2.3 Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2019-2030)

5.3 Global COVID-19 Neutralizing Antibody Drugs Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Tychan

6.1.1 Tychan Corporation Information

6.1.2 Tychan Description and Business Overview

6.1.3 Tychan COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Tychan COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.1.5 Tychan Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Corporation Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.2.4 AstraZeneca COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Molecular Partners AG/诺华

6.3.1 Molecular Partners AG/诺华 Corporation Information

6.3.2 Molecular Partners AG/诺华 Description and Business Overview

6.3.3 Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.3.4 Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.3.5 Molecular Partners AG/诺华 Recent Developments/Updates

6.4 Eli Lilly

6.4.1 Eli Lilly Corporation Information

6.4.2 Eli Lilly Description and Business Overview

6.4.3 Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Eli Lilly COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.4.5 Eli Lilly Recent Developments/Updates

6.5 Regeneron Pharmaceuticals

6.5.1 Regeneron Pharmaceuticals Corporation Information

6.5.2 Regeneron Pharmaceuticals Description and Business Overview

6.5.3 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates

6.6 Abpro

6.6.1 Abpro Corporation Information

6.6.2 Abpro Description and Business Overview

6.6.3 Abpro COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Abpro COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.6.5 Abpro Recent Developments/Updates

6.7 Shanghai Junshi Biosciences

6.6.1 Shanghai Junshi Biosciences Corporation Information

6.6.2 Shanghai Junshi Biosciences Description and Business Overview

6.6.3 Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.7.5 Shanghai Junshi Biosciences Recent Developments/Updates

6.8 Brii Biosciences

6.8.1 Brii Biosciences Corporation Information

6.8.2 Brii Biosciences Description and Business Overview

6.8.3 Brii Biosciences COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Brii Biosciences COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.8.5 Brii Biosciences Recent Developments/Updates

6.9 Mabwell Bioscience

6.9.1 Mabwell Bioscience Corporation Information

6.9.2 Mabwell Bioscience Description and Business Overview

6.9.3 Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.9.5 Mabwell Bioscience Recent Developments/Updates

6.10 Sinocelltech

6.10.1 Sinocelltech Corporation Information

6.10.2 Sinocelltech Description and Business Overview

6.10.3 Sinocelltech COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Sinocelltech COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.10.5 Sinocelltech Recent Developments/Updates

6.11 BeiGene

6.11.1 BeiGene Corporation Information

6.11.2 BeiGene COVID-19 Neutralizing Antibody Drugs Description and Business Overview

6.11.3 BeiGene COVID-19 Neutralizing Antibody Drugs Sales, Revenue and Gross Margin (2019-2024)

6.11.4 BeiGene COVID-19 Neutralizing Antibody Drugs Product Portfolio

6.11.5 BeiGene Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 COVID-19 Neutralizing Antibody Drugs Industry Chain Analysis

7.2 COVID-19 Neutralizing Antibody Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 COVID-19 Neutralizing Antibody Drugs Production Mode & Process

7.4 COVID-19 Neutralizing Antibody Drugs Sales and Marketing

7.4.1 COVID-19 Neutralizing Antibody Drugs Sales Channels

7.4.2 COVID-19 Neutralizing Antibody Drugs Distributors

7.5 COVID-19 Neutralizing Antibody Drugs Customers

8 COVID-19 Neutralizing Antibody Drugs Market Dynamics

8.1 COVID-19 Neutralizing Antibody Drugs Industry Trends

8.2 COVID-19 Neutralizing Antibody Drugs Market Drivers

8.3 COVID-19 Neutralizing Antibody Drugs Market Challenges

8.4 COVID-19 Neutralizing Antibody Drugs Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Tychan

Astrazeneca plc

Abpro

Shanghai Junshi Biosciences

Sinocelltech Ltd

BeiGene Ltd

Molecular Partners AG/诺华

Brii Biosciences

Mabwell Bioscience

Regeneron Pharmaceuticals

Eli Lilly

List of Tables

Table 1. Global COVID-19 Neutralizing Antibody Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global COVID-19 Neutralizing Antibody Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global COVID-19 Neutralizing Antibody Drugs Market Competitive Situation by Manufacturers in 2023

Table 4. Global COVID-19 Neutralizing Antibody Drugs Sales (K Units) of Key Manufacturers (2019-2024)

Table 5. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Manufacturers (2019-2024)

Table 6. Global COVID-19 Neutralizing Antibody Drugs Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market COVID-19 Neutralizing Antibody Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of COVID-19 Neutralizing Antibody Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Product Type & Application

Table 12. Global Key Manufacturers of COVID-19 Neutralizing Antibody Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global COVID-19 Neutralizing Antibody Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Neutralizing Antibody Drugs as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global COVID-19 Neutralizing Antibody Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global COVID-19 Neutralizing Antibody Drugs Sales by Region (2019-2024) & (K Units)

Table 18. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2019-2024)

Table 19. Global COVID-19 Neutralizing Antibody Drugs Sales by Region (2025-2030) & (K Units)

Table 20. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2025-2030)

Table 21. Global COVID-19 Neutralizing Antibody Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2019-2024)

Table 23. Global COVID-19 Neutralizing Antibody Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2025-2030)

Table 25. North America COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2024) & (K Units)

Table 27. North America COVID-19 Neutralizing Antibody Drugs Sales by Country (2025-2030) & (K Units)

Table 28. North America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2024) & (K Units)

Table 32. Europe COVID-19 Neutralizing Antibody Drugs Sales by Country (2025-2030) & (K Units)

Table 33. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe COVID-19 Neutralizing Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific COVID-19 Neutralizing Antibody Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific COVID-19 Neutralizing Antibody Drugs Sales by Region (2019-2024) & (K Units)

Table 37. Asia Pacific COVID-19 Neutralizing Antibody Drugs Sales by Region (2025-2030) & (K Units)

Table 38. Asia Pacific COVID-19 Neutralizing Antibody Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific COVID-19 Neutralizing Antibody Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2024) & (K Units)

Table 42. Latin America COVID-19 Neutralizing Antibody Drugs Sales by Country (2025-2030) & (K Units)

Table 43. Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America COVID-19 Neutralizing Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2019-2024) & (K Units)

Table 47. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales by Country (2025-2030) & (K Units)

Table 48. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global COVID-19 Neutralizing Antibody Drugs Sales (K Units) by Type (2019-2024)

Table 51. Global COVID-19 Neutralizing Antibody Drugs Sales (K Units) by Type (2025-2030)

Table 52. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2019-2024)

Table 53. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Type (2025-2030)

Table 54. Global COVID-19 Neutralizing Antibody Drugs Revenue (US$ Million) by Type (2019-2024)

Table 55. Global COVID-19 Neutralizing Antibody Drugs Revenue (US$ Million) by Type (2025-2030)

Table 56. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2019-2024)

Table 57. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Type (2025-2030)

Table 58. Global COVID-19 Neutralizing Antibody Drugs Price (US$/Unit) by Type (2019-2024)

Table 59. Global COVID-19 Neutralizing Antibody Drugs Price (US$/Unit) by Type (2025-2030)

Table 60. Global COVID-19 Neutralizing Antibody Drugs Sales (K Units) by Application (2019-2024)

Table 61. Global COVID-19 Neutralizing Antibody Drugs Sales (K Units) by Application (2025-2030)

Table 62. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2019-2024)

Table 63. Global COVID-19 Neutralizing Antibody Drugs Sales Market Share by Application (2025-2030)

Table 64. Global COVID-19 Neutralizing Antibody Drugs Revenue (US$ Million) by Application (2019-2024)

Table 65. Global COVID-19 Neutralizing Antibody Drugs Revenue (US$ Million) by Application (2025-2030)

Table 66. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2019-2024)

Table 67. Global COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Application (2025-2030)

Table 68. Global COVID-19 Neutralizing Antibody Drugs Price (US$/Unit) by Application (2019-2024)

Table 69. Global COVID-19 Neutralizing Antibody Drugs Price (US$/Unit) by Application (2025-2030)

Table 70. Tychan Corporation Information

Table 71. Tychan Description and Business Overview

Table 72. Tychan COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 73. Tychan COVID-19 Neutralizing Antibody Drugs Product

Table 74. Tychan Recent Developments/Updates

Table 75. AstraZeneca Corporation Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 78. AstraZeneca COVID-19 Neutralizing Antibody Drugs Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Molecular Partners AG/诺华 Corporation Information

Table 81. Molecular Partners AG/诺华 Description and Business Overview

Table 82. Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 83. Molecular Partners AG/诺华 COVID-19 Neutralizing Antibody Drugs Product

Table 84. Molecular Partners AG/诺华 Recent Developments/Updates

Table 85. Eli Lilly Corporation Information

Table 86. Eli Lilly Description and Business Overview

Table 87. Eli Lilly COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 88. Eli Lilly COVID-19 Neutralizing Antibody Drugs Product

Table 89. Eli Lilly Recent Developments/Updates

Table 90. Regeneron Pharmaceuticals Corporation Information

Table 91. Regeneron Pharmaceuticals Description and Business Overview

Table 92. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 93. Regeneron Pharmaceuticals COVID-19 Neutralizing Antibody Drugs Product

Table 94. Regeneron Pharmaceuticals Recent Developments/Updates

Table 95. Abpro Corporation Information

Table 96. Abpro Description and Business Overview

Table 97. Abpro COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 98. Abpro COVID-19 Neutralizing Antibody Drugs Product

Table 99. Abpro Recent Developments/Updates

Table 100. Shanghai Junshi Biosciences Corporation Information

Table 101. Shanghai Junshi Biosciences Description and Business Overview

Table 102. Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 103. Shanghai Junshi Biosciences COVID-19 Neutralizing Antibody Drugs Product

Table 104. Shanghai Junshi Biosciences Recent Developments/Updates

Table 105. Brii Biosciences Corporation Information

Table 106. Brii Biosciences Description and Business Overview

Table 107. Brii Biosciences COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 108. Brii Biosciences COVID-19 Neutralizing Antibody Drugs Product

Table 109. Brii Biosciences Recent Developments/Updates

Table 110. Mabwell Bioscience Corporation Information

Table 111. Mabwell Bioscience Description and Business Overview

Table 112. Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 113. Mabwell Bioscience COVID-19 Neutralizing Antibody Drugs Product

Table 114. Mabwell Bioscience Recent Developments/Updates

Table 115. Sinocelltech Corporation Information

Table 116. Sinocelltech Description and Business Overview

Table 117. Sinocelltech COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 118. Sinocelltech COVID-19 Neutralizing Antibody Drugs Product

Table 119. Sinocelltech Recent Developments/Updates

Table 120. BeiGene Corporation Information

Table 121. BeiGene Description and Business Overview

Table 122. BeiGene COVID-19 Neutralizing Antibody Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 123. BeiGene COVID-19 Neutralizing Antibody Drugs Product

Table 124. BeiGene Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. COVID-19 Neutralizing Antibody Drugs Distributors List

Table 128. COVID-19 Neutralizing Antibody Drugs Customers List

Table 129. COVID-19 Neutralizing Antibody Drugs Market Trends

Table 130. COVID-19 Neutralizing Antibody Drugs Market Drivers

Table 131. COVID-19 Neutralizing Antibody Drugs Market Challenges

Table 132. COVID-19 Neutralizing Antibody Drugs Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of COVID-19 Neutralizing Antibody Drugs

Figure 2. Global COVID-19 Neutralizing Antibody Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global COVID-19 Neutralizing Antibody Drugs Market Share by Type in 2023 & 2030

Figure 4. ACE2 Fusion Protein Product Picture

Figure 5. Neutralizing Antibody Product Picture

Figure 6. Global COVID-19 Neutralizing Antibody Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global COVID-19 Neutralizing Antibody Drugs Market Share by Application in 2023 & 2030

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Global COVID-19 Neutralizing Antibody Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 11. Global COVID-19 Neutralizing Antibody Drugs Market Size (2019-2030) & (US$ Million)

Figure 12. Global COVID-19 Neutralizing Antibody Drugs Sales (2019-2030) & (K Units)

Figure 13. Global COVID-19 Neutralizing Antibody Drugs Average Price (US$/Unit) & (2019-2030)

Figure 14. COVID-19 Neutralizing Antibody Drugs Report Years Considered

Figure 15. COVID-19 Neutralizing Antibody Drugs Sales Share by Manufacturers in 2023

Figure 16. Global COVID-19 Neutralizing Antibody Drugs Revenue Share by Manufacturers in 2023

Figure 17. The Global 5 and 10 Largest COVID-19 Neutralizing Antibody Drugs Players: Market Share by Revenue in 2023

Figure 18. COVID-19 Neutralizing Antibody Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 19. Global COVID-19 Neutralizing Antibody Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 20. North America COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2019-2030)

Figure 21. North America COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2019-2030)

Figure 22. United States COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 23. Canada COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 24. Europe COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2019-2030)

Figure 25. Europe COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2019-2030)

Figure 26. Germany COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. France COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. U.K. COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Italy COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. Russia COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. Asia Pacific COVID-19 Neutralizing Antibody Drugs Sales Market Share by Region (2019-2030)

Figure 32. Asia Pacific COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Region (2019-2030)

Figure 33. China COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Japan COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. South Korea COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. India COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Australia COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. China Taiwan COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Southeast Asia COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Latin America COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2019-2030)

Figure 41. Latin America COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2019-2030)

Figure 42. Mexico COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Brazil COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Argentina COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Sales Market Share by Country (2019-2030)

Figure 46. Middle East & Africa COVID-19 Neutralizing Antibody Drugs Revenue Market Share by Country (2019-2030)

Figure 47. Turkey COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Saudi Arabia COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. UAE COVID-19 Neutralizing Antibody Drugs Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Global Sales Market Share of COVID-19 Neutralizing Antibody Drugs by Type (2019-2030)

Figure 51. Global Revenue Market Share of COVID-19 Neutralizing Antibody Drugs by Type (2019-2030)

Figure 52. Global COVID-19 Neutralizing Antibody Drugs Price (US$/Unit) by Type (2019-2030)

Figure 53. Global Sales Market Share of COVID-19 Neutralizing Antibody Drugs by Application (2019-2030)

Figure 54. Global Revenue Market Share of COVID-19 Neutralizing Antibody Drugs by Application (2019-2030)

Figure 55. Global COVID-19 Neutralizing Antibody Drugs Price (US$/Unit) by Application (2019-2030)

Figure 56. COVID-19 Neutralizing Antibody Drugs Value Chain

Figure 57. COVID-19 Neutralizing Antibody Drugs Production Process

Figure 58. Channels of Distribution (Direct Vs Distribution)

Figure 59. Distributors Profiles

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions